Key result
N-terminal probrain natriuretic peptide levels were significantly higher in cardioembolic versus noncardioembolic ischemic stroke (491.6 vs 124.7 pg/ml, P<0.001), yielding an AUC of 0.77.
Why the study?
Does NT-proBNP accurately identify cardioembolic stroke in acute stroke patients?
Observational (n=92)
Does NT-proBNP accurately identify cardioembolic stroke in acute stroke patients?
Effect estimate: AUC 0.77
Absolute Event Rate: 491.6% vs 124.7%
p-value: p=<0.001
NT-proBNP is a highly accurate biomarker for identifying cardioembolic stroke, particularly those associated with atrial fibrillation, which may help guide secondary prevention.
NT-proBNP may aid cardioembolic stroke identification; leaves open prospective validation before diagnostic use.
BACKGROUND: and purpose N-terminal probrain natriuretic peptide, which is mainly produced by the heart, is increased in acute stroke. We aimed to determine if N-terminal probrain natriuretic peptide could be a biomarker for ischemic stroke with a cardioembolic cause. METHODS: Consecutive sample of acute stroke patients admitted to a Stroke Unit. Ischemic stroke subtype was classified using the TOAST classification. Blood samples were drawn within 72 h after stroke onset. Serum N-terminal probrain natriuretic peptide concentration was measured using an electrochemiluminescence immunoassay. Mean values of N-terminal probrain natriuretic peptide were compared between patients with hemorrhagic stroke vs. ischemic stroke, cardioembolic stroke vs. noncardioembolic stroke, cardioembolic stroke with atrial fibrillation vs. noncardioembolic stroke using t-test. Receiver operating characteristic curves were used to test the ability of N-terminal probrain natriuretic peptide values to identify cardioembolic stroke and cardioembolic stroke with atrial fibrillation. RESULTS: Ninety-two patients were included (66 with ischemic stroke) with a mean age of 58·6 years. Twenty-eight (42·4%) ischemic strokes had a cardioembolic cause. Mean N-terminal probrain natriuretic peptide values for cardioembolic stroke were significantly higher (P<0·001) (491·6; 95% confidence interval 283·7-852·0 pg/ml) than for noncardioembolic ischemic stroke (124·7; 86·3-180·2 pg/ml). The area under the receiver operating characteristic curve for N-terminal probrain natriuretic peptide in cardioembolic stroke was 0·77. The cut-off point with the highest sensitivity and specificity was set at 265·5 pg/ml (71·4% and 73·7% respectively). The area under the curve of N-terminal probrain natriuretic peptide for cardioembolic stroke related to atrial fibrillation was 0·92, cut-off was set at 265·5 pg/ml (sensitivity 94·4%, specificity 72·9%). CONCLUSION: N-terminal probrain natriuretic peptide is a biomarker with a good accuracy to predict ischemic stroke of cardioembolic cause, namely associated with atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Fonseca et al. (2011) conducted an observational in Acute stroke (n=92). N-terminal probrain natriuretic peptide was evaluated on Cardioembolic stroke identification (AUC 0.77, p=<0.001). N-terminal probrain natriuretic peptide levels were significantly higher in cardioembolic versus noncardioembolic ischemic stroke (491.6 vs 124.7 pg/ml, P<0.001), yielding an AUC of 0.77.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: